Enhancing Rapid Detection and Quantification of COVID-19 Antibodies using Quartz Crystal Microbalance

Vincent de Avelar, Cindy Hoang, Brandon Huynh, Yonas Kiflemariam, Hugues Kutambula, Olivia Thompson, & Dr. Finke

Healthcare systems faced unprecedented challenges during the COVID-19 pandemic, grappling with overwhelming patient loads and a need for efficient diagnostic tools. Considering this, it has become imperative to develop diagnostic systems that meet the complexities of modern patient care. To address these concerns, we conducted research focusing on the development of an enhanced antibody detection and quantification tool designed to identify blood serum SARSCoV-2 antibody levels. Our primary objective was to explore the feasibility of a plug-and-play mobile device incorporating guartz crystal resonance sensors as the foundation for an improved rapid test for SARS-CoV-2 seropositivity. Our innovation incorporates antibody quantification - an invaluable aspect in managing the pandemic effectively - and a device possessing the capability to accurately detect variations in molecular mass within the applied serum. To gauge the detected mass differences when antibodies are bound, we conducted tests with both the receptor binding domain and the whole spike protein and analyzed the differences. Introducing each component to the sensor showed distinct resonances, which could be translated into mass data and analyzed to determine seropositivity. Due to unforeseen circumstances, we are not able to analyze any data. The hope for future research is to streamline this machinery into an efficient and portable test for rural regions and be able to determine levels of seropositivity based on the mass difference after antibody binding. With this data we hope to be able to determine whether patients need treatment and effectiveness of various treatments.